AU2018280871B2 - CD38 modulating antibody - Google Patents

CD38 modulating antibody Download PDF

Info

Publication number
AU2018280871B2
AU2018280871B2 AU2018280871A AU2018280871A AU2018280871B2 AU 2018280871 B2 AU2018280871 B2 AU 2018280871B2 AU 2018280871 A AU2018280871 A AU 2018280871A AU 2018280871 A AU2018280871 A AU 2018280871A AU 2018280871 B2 AU2018280871 B2 AU 2018280871B2
Authority
AU
Australia
Prior art keywords
antibody
acd38
seq
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018280871A
Other languages
English (en)
Other versions
AU2018280871A8 (en
AU2018280871A1 (en
Inventor
Hemanta Baruah
Nina EISSLER
Simone FILOSTO
Anne Goubier
Beatriz GOYENECHEA CORZO
Pascal Merchiers
Kevin Moulder
Bianka Prinz
Josephine SALIMU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Belt Therapeutics Ltd
Original Assignee
Black Belt Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Therapeutics Ltd filed Critical Black Belt Therapeutics Ltd
Publication of AU2018280871A1 publication Critical patent/AU2018280871A1/en
Publication of AU2018280871A8 publication Critical patent/AU2018280871A8/en
Application granted granted Critical
Publication of AU2018280871B2 publication Critical patent/AU2018280871B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018280871A 2017-06-08 2018-06-08 CD38 modulating antibody Active AU2018280871B2 (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,150 2017-06-08
US62/517,149 2017-06-08
US201762517740P 2017-06-09 2017-06-09
US201762517745P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US62/517,740 2017-06-09
US62/517,734 2017-06-09
US62/517,745 2017-06-09
US62/517,753 2017-06-09
US62/517,164 2017-06-09
US62/517,165 2017-06-09
US201762582666P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US62/582,666 2017-11-07
US62/582,653 2017-11-07
US62/582,681 2017-11-07
US62/582,676 2017-11-07
PCT/EP2018/065243 WO2018224685A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Publications (3)

Publication Number Publication Date
AU2018280871A1 AU2018280871A1 (en) 2020-01-16
AU2018280871A8 AU2018280871A8 (en) 2020-01-30
AU2018280871B2 true AU2018280871B2 (en) 2024-09-26

Family

ID=62620847

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018280871A Active AU2018280871B2 (en) 2017-06-08 2018-06-08 CD38 modulating antibody
AU2018280869A Active AU2018280869B2 (en) 2017-06-08 2018-06-08 CD38 modulating antibody
AU2025201908A Pending AU2025201908A1 (en) 2017-06-08 2025-03-17 CD38 modulating antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018280869A Active AU2018280869B2 (en) 2017-06-08 2018-06-08 CD38 modulating antibody
AU2025201908A Pending AU2025201908A1 (en) 2017-06-08 2025-03-17 CD38 modulating antibody

Country Status (8)

Country Link
US (3) US12343394B2 (cg-RX-API-DMAC7.html)
EP (2) EP3635002A1 (cg-RX-API-DMAC7.html)
JP (3) JP7237951B2 (cg-RX-API-DMAC7.html)
KR (3) KR102719065B1 (cg-RX-API-DMAC7.html)
CN (2) CN110997722B (cg-RX-API-DMAC7.html)
AU (3) AU2018280871B2 (cg-RX-API-DMAC7.html)
CA (2) CA3066553A1 (cg-RX-API-DMAC7.html)
WO (2) WO2018224685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
CA3127520A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体
EP4211476A4 (en) * 2020-09-10 2024-11-13 CASI Pharmaceuticals, Inc. BLOOD SCREENING PROCEDURES
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071355A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
NZ586780A (en) 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2342220B1 (en) 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
BR112012006388B1 (pt) 2009-09-22 2022-01-04 Probiogen Ag Método para produzir uma molécula, e, método para produzir uma proteína
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015021521A2 (pt) 2013-03-15 2017-10-10 Genentech Inc anticorpos anti-crth2 e métodos para seu uso
WO2015123687A1 (en) 2014-02-14 2015-08-20 Centrose, Llc Extracellular targeted drug conjugates
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
KR20170085131A (ko) 2014-12-01 2017-07-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Dna 항체 작제물 및 그 이용 방법
EP3280443B1 (en) 2015-04-08 2022-08-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
PT3313441T (pt) 2015-06-24 2024-05-07 Janssen Biotech Inc Modulação imunitária e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
RU2761115C1 (ru) 2015-10-02 2021-12-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
EP4036116A4 (en) 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071355A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Also Published As

Publication number Publication date
CN110997722B (zh) 2023-09-26
JP7237951B2 (ja) 2023-03-13
CN110997722A (zh) 2020-04-10
US20210277138A1 (en) 2021-09-09
CA3066553A1 (en) 2018-12-13
AU2018280871A8 (en) 2020-01-30
CN110997723A (zh) 2020-04-10
US12343394B2 (en) 2025-07-01
KR20200021069A (ko) 2020-02-27
US12161717B2 (en) 2024-12-10
KR20250025514A (ko) 2025-02-21
JP7467584B2 (ja) 2024-04-15
JP2023030071A (ja) 2023-03-07
AU2018280869B2 (en) 2025-01-02
EP3635002A1 (en) 2020-04-15
CN110997723B (zh) 2023-09-26
KR102770106B1 (ko) 2025-02-21
AU2025201908A1 (en) 2025-04-03
CA3066555A1 (en) 2018-12-13
KR102719065B1 (ko) 2024-10-17
NZ760448A (en) 2025-03-28
JP7237950B2 (ja) 2023-03-13
KR20200021068A (ko) 2020-02-27
AU2018280869A1 (en) 2020-01-16
EP3635003A1 (en) 2020-04-15
US20250367286A1 (en) 2025-12-04
NZ760342A (en) 2025-03-28
AU2018280871A1 (en) 2020-01-16
JP2020522280A (ja) 2020-07-30
US20230103584A1 (en) 2023-04-06
WO2018224685A1 (en) 2018-12-13
WO2018224683A1 (en) 2018-12-13
JP2020522281A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
US20250367286A1 (en) Cd38 modulating antibody agents
JP7596447B2 (ja) Ｃｄ３８調節抗体
US12162949B2 (en) CD38 antibody
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 2 , PAGE(S) 228 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BLACK BELT THERAPEUTICS LTD, APPLICATION NO. 2018280871, UNDER INID (72) CORRECT THE CO-INVENTOR TO GOYENECHEA CORZO, BEATRIZ

FGA Letters patent sealed or granted (standard patent)